Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Cancer-Associated Myositis and Anti-p155 Autoantibody in a Series of 85 Patients with Idiopathic Inflammatory Myopathy
Medicine 89:47-52, Trallero-Araguas,E.,et al, 2010
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
Hiccups, Nausea, and Vomiting: Water Channels Under Attack
Lancet 375:394, Riphagen,J.,et al, 2010
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Longitudinally Extensive Myelopathy in Caucasians: A West Australian Study of 26 Cases from the Perth Demyelinating Diseases Database
JNNP 81:209-212, Qiu,W.,et al, 2010
Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010
Giant Urticaria and Persistent Neutralizing Antibodies After the First Natalizumab Infusion
Neurol 74:1394-1395, Cohen,M., et al, 2010
Clinicopath Conf., Progressive Multifocal Leukoencephalopathy
NEJM 362:1431-1437, Case 11-2010, 2010
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Treatment of Refractory Neurosarcoidosis with Infliximab
JNNP 81:241-246, Santos,E., et al, 2010
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
Acute and Preventive Pharmacologic Treatment of Cluster Headache
Neurol 75:463-473, Francis,G.J., et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Acute Toxoplasmosis Infection in a Patient with Ankylosing Spondylitis Treated with Adalimumab: A Case Report
Reumatismo 62:283-285, Azevedo V.F., et al, 2010
Periarteritis Nodosa
www.MedLink.com, June, Ramachandran, T. & Roos, R., 2010
Non-Infectious Endocarditis in a Patient with cANCA-associated Small Vessel Vasculitis
Rheumatology 48:592-594, Horino, T.,et al, 2009
Multiple Bilateral Non-Hemorrhagic Cerebral Infarctions Associated with Microscopic Polyangiitis
Clin Neurol Neurosurg 111:904-906, Ku, B. & Shin, H., 2009
Microscopic Polyangiitis Presenting with Capsular Warning Syndrome and Subsequent Stroke
J Neurol Sci 277:174-175, Tang, C.,et al, 2009
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Pathologic and Immunologic Profiles of a Limited Form of Neuromyelitis Optica with Myelitis
Neurol 73:1628-1637, Yanagawa,K.,et al, 2009
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Lyme Neuroborreliosis: Manifestations of a Rapidly Emerging Zoonosis
AJNR 30:1079-1087, Hildenbrand,P.,et al, 2009
Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Clinicopath Conf, Neurosarcoidosis
NEJM 360:802-809, Case 6-2009, 2009
Posterior Reversible Encephalopathy Syndrome in Neuromyelitis Optica Spectrum Disorders
Neurol 72:712-717, Maga�a,S.M.,et al, 2009
Slurred Speech and Spirochaetes
Lancet 373:978, Thukral,A.,et al, 2009
NMO-IgG Detected in CSF in Seronegative Neuromyelitis Optica
Neurol 72:1101-1003, Klawiter,E.C.,et al, 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009